Evidence map›Paper›PMID 38173939›Full record

ArticleFrontiers in medicine2023

Screening and validation of double allele-specific binding F-primers for the measurement of antihypertensive pharmacogenomics.

Yang Ping, Su Quanlin, Hu Yue, Zhang Jing, Lan Wenjun

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 73% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yang Ping *Institute of Biomedical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, Shandong, China.
Su Quanlin *Institute of Biomedical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, Shandong, China.
Hu YueInstitute of Biomedical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, Shandong, China.
Zhang JingInstitute of Biomedical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, Shandong, China.
Lan WenjunInstitute of Biomedical Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan, Shandong, China.
Qilu University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Previous studies have proposed that genetic polymorphisms of CYP2D6 Methods: To establish a quadruplex quantitative PCR (qPCR) analysis for genotyping of CYP2D6 Results: Seven pairs of primers were successfully selected through three rounds of F-primers screening. Except for ADRB1, the robustness assessment showed the amplification efficiency ranging from 0.9 to 1.1. In agreement analysis, two specimens in the training set (n = 203) were defined by the triplex analysis rather than NGS as heterozygotes for ACE, which was evidenced by gel electrophoresis. Reproducibility evaluation demonstrated that the coefficient of variation (CV) was <5%. Conclusion: Multiplex amplification analysis using screened AS binding primers is a simple, reliable, and accurate tool to guide drug delivery in antihypertensive personalized treatment.

Indexed as

allele-specific (AS)antihypertensiveF-primersgenotypingpolymorphism

Identifiers

PMID38173939
PMCPMC10761462
OpenAlexW4390038397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.